Podcast Episodes
Back to Search
Daily Roundup | GSK Ends Alector Neuroscience Bet: What the $2.2B Unwind Signals
GSK walked away from its $2.2 billion Alector alliance, ending its neuroscience re-entry as clinical setbacks piled up. Plus: the FDA resumes releasi…
1 week, 6 days ago
Daily Roundup | Wainua Fails Pivotal ATTR-CM Trial; Ionis Sinks 20%
AstraZeneca and Ionis's Wainua missed its Phase 3 ATTR-CM endpoint — Ionis fell ~20% while BridgeBio surged ~17%. We break down the CARDIO-TTRansform…
2 weeks ago
Daily Roundup | FDA Halts Drug Rejection Letters — What It Means for Competitive Intel
The FDA quietly paused publishing complete response letters after a citizen petition — reversing the Makary-era transparency push and closing a live …
2 weeks, 1 day ago
Daily Roundup | Vera's TRUTAKNA Wins FDA Nod: The eGFR Readout That Decides the IgAN Race
Vera Therapeutics wins FDA accelerated approval for TRUTAKNA (atacicept) in IgA nephropathy on a 42% placebo-adjusted proteinuria cut — setting up a …
2 weeks, 2 days ago
Daily Roundup | Vertex Buys Crinetics for $10B in Endocrinology Push
Vertex pays $10B cash for Crinetics Pharmaceuticals — its largest deal ever — betting on acromegaly drug Palsonify and Phase 3 CAH candidate atumelna…
2 weeks, 3 days ago
Enbrel Price Cap Blocked: One Ruling That Could Reshape States Drug Pricing
Federal court blocks Colorado's 70% price cap on Enbrel — ruling could shut down state drug pricing laws nationwide. Plus: Casgevy label expansion to…
2 weeks, 6 days ago
Roche Divarasib Beats Both KRAS G12C Rivals in Phase 3 Lung Cancer Study
Roche's divarasib beats both KRAS G12C rivals on PFS and OS in head-to-head Phase 3, hitting survival significance at interim. AstraZeneca returns to…
2 weeks, 6 days ago
July 01, 2026| Tregzi Approved — Orca Bio Opens a New Lane in Cell Therapy
FDA approves Orca Bio's Tregzi — the first precision-engineered cell therapy for allogeneic transplant, sparking IPO speculation. Plus BridgeBio secu…
3 weeks, 1 day ago
Jun 30, 2026 | NEJM Retracts Tavneos Pivotal Trial; Ionis Tryngolza PDUFA Today
NEJM retracts Amgen's ADVOCATE study after FDA findsendpoint data for 9 patients re-evaluated post-unblinding. Plus: Ionis faces the Tryngolza sNDA P…
3 weeks, 2 days ago
Jun 29, 2026 | Orforglipron PDUFA Tomorrow: Lilly Trades Above Consensus
Lilly at $1,230 — trading above analyst consensus — as orforglipron faces its FDA verdict tomorrow. Three label items to watch beyond the headline, p…
3 weeks, 3 days ago